ContractLicense Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionEX-10.1 2 opiant-adaptlicenseagreeme.htm EXHIBIT 10.1 Exhibit 10.1 Confidential Treatment has been granted for portions of this exhibit. The copy filed herewith omits certain information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT between LIGHTLAKE THERAPEUTICS INC. and ADAPT PHARMA OPERATIONS LIMITED Dated as of December 15, 2014 Exhibit 10.1 Confidential Treatment has been granted for portions of this exhibit. The copy filed herewith omits certain information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT This License Agreement (the “Agreement”) is made and entered into effective as of December 15, 2014 (the “Effective Date”) by and between Lightlake Therapeutics Inc., a Nevada co
LICENSE AGREEMENTLicense Agreement • March 5th, 2018 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
Contract Type FiledMarch 5th, 2018 Company Industry JurisdictionThis License Agreement (the “Agreement”) is made and entered into effective as of December 15, 2014 (the “Effective Date”) by and between Lightlake Therapeutics Inc., a Nevada corporation (“Lightlake”), and Adapt Pharma Operations Limited, an Irish limited company (“Adapt”). Lightlake and Adapt are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENT between LIGHTLAKE THERAPEUTICS INC. and ADAPT PHARMA OPERATIONS LIMITED Dated as of December 15, 2014License Agreement • April 19th, 2017 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
Contract Type FiledApril 19th, 2017 Company Industry JurisdictionThis License Agreement (the “Agreement”) is made and entered into effective as of December 15, 2014 (the “Effective Date”) by and between Lightlake Therapeutics Inc., a Nevada corporation (“Lightlake”), and Adapt Pharma Operations Limited, an Irish limited company (“Adapt”). Lightlake and Adapt are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.